Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Infectious disease R&D Pipeline

Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Programs 1,112

Quick answer

Infectious disease: NovaPharmaNews indexes 1,112 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Top sponsors

Pipeline programs

Page 13 of 24

  1. Subcutaneous injection of TAK-850

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  2. TAK-019

    Takeda

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  3. TAK-850

    Takeda

    Influenza Infection

    phase 2 mab completed

    1 trial

  4. TAK-850 0.5 mL injection

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  5. TAK-919

    Takeda

    Coronavirus Disease (COVID-19)

    phase 2 mab completed

    1 trial

  6. TD-0903

    Theravance Biopharma Ireland Umited

    Acute Lung Injury (ALI) Associated With COVID-19

    phase 2 small molecule completed

    2 trials

  7. TD-1792

    Theravance Biopharma Ireland Umited

    Staphylococcal Skin Infection

    phase 2 small molecule completed

    1 trial

  8. TENOFOVIR ALAFENAMIDE for Hepatitis B and Hepatitis D Viral Co-infection

    Janssen-Cilag International N.V.

    Hepatitis B and Hepatitis D Viral Co-infection

    phase 2 small molecule active

    1 trial

  9. TEV-45478

    Teva Pharma GmbH

    Nonalcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  10. TG-873870 (Nemonoxacin)

    Biotech Pharmaceutical Co.,

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  11. THALASSA 2.0

    MEDA Pharma GmbH & Co. KG

    post-COVID-19 Condition (PCC)

    phase 2 small molecule active

    1 trial

  12. TMC435

    Elan Pharma International

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  13. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

    phase 2 small molecule completed

    1 trial

  14. TOPIRAMATE

    Disc Medicine

    human immunodeficiency virus 1 (HIV-1)

    phase 2 small molecule active

    1 trial

  15. TVB-2640

    Sagimet Biosciences

    Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  16. TVB-2640 25 mg (US)

    Sagimet Biosciences

    MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

    phase 2 small molecule completed

    1 trial

  17. Tafenoquine Oral Tablet

    60 DEGREES PHARMACEUTICALS, INC.

    COVID 19 Disease

    phase 2 small molecule completed

    1 trial

  18. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  19. Telaprevir and Sofosbuvir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  20. Telavancin

    Theravance Biopharma Ireland Umited

    Infection

    phase 2 small molecule completed

    1 trial

  21. Telavancin

    CUMBERLAND PHARMACEUTICALS INC

    Infections, Gram-Positive Bacterial

    phase 2 small molecule completed

    2 trials

  22. Telavancin

    CUMBERLAND PHARMACEUTICALS INC

    Gram-Positive Bacterial Infections

    phase 2 small molecule terminated

    2 trials

  23. Tenofovir Alafenamide

    Vir Biotechnology

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial

  24. Tenofovir gel

    United Therapeutics Europe Ltd

    HIV Infections

    phase 2 small molecule completed

    1 trial

  25. Tenofovir/lamivudine/lopinavir-ritonavir

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 2 small molecule completed

    1 trial

  26. Theory-based counseling program

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 other completed

    1 trial

  27. Tipranavir

    Boehringer Ingelheim

    HIV Infections

    phase 2 small molecule completed

    1 trial

  28. UB-421

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV-1-infection

    phase 2 mab active

    1 trial

  29. UB-421(25 mg/kg) Q2W

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV-1-infection

    phase 2 mab active

    1 trial

  30. UB-421(25 mg/kg) Q2W

    United Therapeutics Europe Ltd

    HIV-1 Infection

    phase 2 mab completed

    1 trial

  31. UB-612

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab completed

    4 trials

  32. UBT251

    United Therapeutics Europe Ltd

    Metabolic Dysfunction-associated Steatohepatitis (MASH)

    phase 2 small molecule active

    1 trial

  33. UC-MSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cirrhosis Due to Hepatitis B

    phase 2 mab active

    1 trial

  34. UK-453,061 Dose 1

    Pfizer

    HIV-1

    phase 2 small molecule terminated

    1 trial

  35. Ursodeoxycholic acid

    Hospital Authority, Hong Kong

    Hepatitis D

    phase 2 small molecule active

    1 trial

  36. Ursodeoxycholic acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 small molecule completed

    1 trial

  37. VAC059

    United Therapeutics Europe Ltd

    Plasmodium Falciparum Malaria

    phase 2 mab completed

    1 trial

  38. VBR

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  39. VCH-222 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  40. VCH-759 (BCH-27759)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  41. VIR-2218

    Alnylam Netherlands B.V.

    Chronic Hepatitis B

    phase 2 small molecule completed

    2 trials

  42. VIR-2218

    Vir Biotechnology

    Hepatitis D, Chronic

    phase 2 small molecule active

    1 trial

  43. VIR-2218

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  44. VIR-2218

    Alnylam Netherlands B.V.

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  45. VIR-2218

    Vir Biotechnology

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial

  46. VIR-2218-1006

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  47. VIR-3434

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  48. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many infectious disease pipeline programs are tracked?

1,112 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.